Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vintafolide
- Development stage
- Phase 3
- Lead developer
- Novartis
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Vintafolide is a targeted cancer therapeutic that consists of a folic acid moiety linked to the vinca alkaloid desacetylvinblastine monohydrazide (DAVLBH). It is designed to selectively deliver cytotoxic chemotherapy to cancer cells that overexpress the folate receptor, such as those found in ovarian and certain other solid tumors. The drug binds to the folate receptor on tumor cells, is internalized via endocytosis, and then releases its cytotoxic payload inside the cell through a proprietary linker mechanism. This approach aims to minimize off-target toxicity by sparing normal tissues with low or absent folate receptor expression. Vintafolide was developed primarily for use in platinum-resistant ovarian cancer, often in combination with pegylated liposomal doxorubicin (PLD), and was investigated alongside a companion diagnostic imaging agent (etarfolatide) for patient selection[1][2][4][5].
- Brand names
- Vynfinit
- Other names
- vintafolidumDesacetylvinblastine hydrazide conjugate with folic acidFolate-vinca alkaloid conjugate EC145
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on vintafolide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vintafolide.